Clarity Pharmaceuticals (CU6) - O/W: Better Late than Fuzzy
Evaluation of Clarity’s opportunity with their 64Cu-SARbisPSMA PET/CT agent in prostate cancer drives our upgrade in part – recognising that they...
299 Views
Clarity Pharmaceuticals (CU6) - Cash for Copper
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.12/sh (unrisked $7.71/sh). Clarity have recently...
419 Views
Clarity Pharmaceuticals (CU6) - More SECuRE than Ever
Clarity have provided the market with new positive data from both their diagnostic (COBRA) and therapeutic (SECuRE) PSMA prostate cancer (PC)...
344 Views
Clarity Pharmaceuticals (CU6) - More Positive Data SECuREd
Clarity have announced further positive data from their ongoing Phase I/IIa theranostic trial in mCRPC with 64Cu-/67Cu-SAR-bisPSMA.
334 Views
Clarity Pharmaceuticals (CU6) - Lesion Size: A New Potential Differentiator
Clarity have released further data from their Phase II COBRA trial evaluating their 64Cu-SAR- bisPSMA PET diagnostic agent in suspected biochemical...
342 Views